Protara Therapeutics (NASDAQ:TARA) Upgraded by Wall Street Zen to Sell Rating

Wall Street Zen upgraded shares of Protara Therapeutics (NASDAQ:TARA) from a strong sell rating to a sell rating in a research report report published on Saturday,Wall Street Zen reports.

Several other research analysts also recently commented on TARA. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Protara Therapeutics in a research note on Wednesday, May 20th. UBS Group reiterated a “buy” rating on shares of Protara Therapeutics in a research note on Wednesday, May 20th. Oppenheimer raised their target price on shares of Protara Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Protara Therapeutics in a report on Friday, July 17th. Finally, HC Wainwright reissued a “buy” rating on shares of Protara Therapeutics in a research note on Wednesday, May 20th. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $26.25.

Protara Therapeutics Price Performance

Shares of Protara Therapeutics stock opened at $3.94 on Friday. The stock has a market capitalization of $232.85 million, a PE ratio of -2.92 and a beta of 1.49. Protara Therapeutics has a 1-year low of $3.02 and a 1-year high of $7.82. The company’s fifty day simple moving average is $4.01 and its 200-day simple moving average is $4.72.

Protara Therapeutics (NASDAQ:TARA) last announced its earnings results on Tuesday, August 11th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.03). As a group, research analysts anticipate that Protara Therapeutics will post -1.48 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP grew its holdings in Protara Therapeutics by 133.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 531,267 shares of the company’s stock valued at $2,767,000 after buying an additional 304,110 shares in the last quarter. AIGH Capital Management LLC purchased a new position in shares of Protara Therapeutics in the first quarter worth $8,454,000. UBS Group AG lifted its holdings in shares of Protara Therapeutics by 44.2% in the fourth quarter. UBS Group AG now owns 1,215,537 shares of the company’s stock worth $6,479,000 after buying an additional 372,463 shares in the last quarter. Walleye Capital LLC boosted its position in shares of Protara Therapeutics by 204.0% during the first quarter. Walleye Capital LLC now owns 443,401 shares of the company’s stock worth $2,310,000 after acquiring an additional 297,525 shares during the last quarter. Finally, Bank of America Corp DE boosted its position in shares of Protara Therapeutics by 86.7% during the first quarter. Bank of America Corp DE now owns 925,918 shares of the company’s stock worth $4,824,000 after acquiring an additional 430,014 shares during the last quarter. 38.13% of the stock is owned by hedge funds and other institutional investors.

About Protara Therapeutics

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.